Copyright
©The Author(s) 2015.
World J Hepatol. Apr 8, 2015; 7(4): 673-687
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.673
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.673
Table 1 Phase III trials of some systemic targeted agents in advanced hepatocellular carcinoma
| Ref. | Study design | Patients, n | Overall survival, mo |
| Zhu et al[109] (SEARCH trial) | Sorafenib vs sorafenib + erlotinib | 358 vs 362 | Sorafenib: 8.5 Sorafenib + erlotinib: 9.5 |
| Cheng et al[105] (SUN1170 trial) | Sorafenib vs sunitinib | 544 vs 530 | Sorafenib: 10.2 Sunitinib: 7.9 |
| Cainap et al[106] (LIGHT trial) | Sorafenib vs linifanib | 517 vs 518 | Sorafenib: 9.8 Linifanib: 9.1 |
| Johnson et al[107] (BRISK-FL trial) | Sorafenib vs brivanib | 578 vs 577 | Sorafenib: 9.9 Brivanib: 9.5 |
| Llovet et al[108] (BRISK-PS trial) | Brivanib vs placebo | 263 vs 132 | Brivanib: 9.4 Placebo: 8.3 |
- Citation: Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687
- URL: https://www.wjgnet.com/1948-5182/full/v7/i4/673.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i4.673